Monday, March 02, 2015 9:10:43 AM
George, All good points. Frost is known for his end-arounds and halfback option plays. Makes the Patriots playbook seem straightforward.
I remember how frustrated I was when - with no warning - BZNE just sold all of it's IP and programs to MSLP in return for MSLP shares, then the reverse merger of BZNE and what became COCP, and then another merger. It would be good to have a program so we know who the players are.
Steve
I remember how frustrated I was when - with no warning - BZNE just sold all of it's IP and programs to MSLP in return for MSLP shares, then the reverse merger of BZNE and what became COCP, and then another merger. It would be good to have a program so we know who the players are.
Steve
All I say is IMHO and not to be construed as investment advice. I know nothing, as informed frequently by my wife.
Recent COCP News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/23/2026 09:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:30:27 PM
- Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive • GlobeNewswire Inc. • 04/02/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 12:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 12:30:22 PM
- Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 12:30:32 PM
- First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment • GlobeNewswire Inc. • 03/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 01:30:54 PM
- Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 • GlobeNewswire Inc. • 02/19/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:10:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:10:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 02:00:25 PM
- Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus • GlobeNewswire Inc. • 12/18/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 09:30:29 PM
- Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference • GlobeNewswire Inc. • 12/01/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 01:30:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 01:00:58 PM
- Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 11/14/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/30/2025 08:15:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 12:00:37 PM
- Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 10/30/2025 12:00:00 PM
